SLNO
vs
S&P 500

Over the past 12 months, SLNO has significantly outperformed S&P 500, delivering a return of 80% compared to the S&P 500's 10% growth.
Performance By Year
SLNO vs S&P 500
Soleno Therapeutics Inc
Glance View
Soleno Therapeutics Inc. is a biopharmaceutical company centered on the pressing needs of rare disease patients, most notably those with Prader-Willi syndrome (PWS). This congenital condition, characterized by an insatiable appetite leading to chronic overeating and subsequent obesity, poses significant health risks. Soleno targets this niche through its pioneering drug candidate, DCCR (diazoxide choline controlled-release), which aims to regulate appetite and improve quality of life for PWS patients. By focusing its primary efforts on this orphan indication, Soleno seeks to capitalize on favorable regulatory designations and expedited pathways, affording them advantages in both development timelines and market exclusivity. The company generates revenue through strategic partnerships, research grants, and potential future product sales, assuming regulatory approval of DCCR. One of their key strategies involves engaging with patient advocacy groups and the broader medical community to underscore the unmet needs in PWS and illustrate the potential of DCCR. Additionally, by exploring broader applications of their core technology, Soleno aims to diversify their pipeline, thus enhancing shareholder value and reinforcing their stronghold in the rare disease pharmaceutical sector. The company’s focus on innovation and collaboration, combined with a keen understanding of the regulatory landscape, positions it to navigate the complexities of biopharmaceutical market competition successfully.
